continu believ futur categori depend reduc
risk product like iqo juul smokeless tobacco though regulatori clariti juul
fda approv statu flavor etc like remain year away expect iqo
take center stage meantim believ stand benefit vapor-fre smoke-
free option consum nation launch could add signific spend
yet model though invest would right move long-term
also trim ep lower expect juul equiti incom
deal genesi still unknown like organ evolut motiv
origin pm altria merger talk kept confidenti two
histor closer contact may realiz talk like evolv
organ may first appreci one focu like deeper
pocket combin entiti would fund us launch iqo may
potenti faster growth two could agre term unfavor
investor feedback rise us vapor issu like also help derail deal
iqo smokeless vapor focu futur cigarett price much
manag consum modest price hike easier typic
volum declin declin believ elev declin
manag near-term persist believ altria long-term focu non-
combust altern like iqo moist snuff stake juul success
key ep growth algorithm recent vapor concern sentiment
headwind even concern may ultim benefit cigarett categori trend
come question regul consum mind believ make
us iqo launch time appar consid bigger invest push
part merger think believ altria may still invest aggress nation
roll-out iqo would sure right move long-term could
weigh ep growth may closer growth long-
term target yet includ elev spend model
appoint new juul ceo posit juul name crosthwait
ceo effect immedi crosthwait import regulatori experi
industri knowledg believ need juul goe pmta
process obtain fda author howev given fda plan remov flavor
vapor product market juul sale lower equiti incom
contribut partial off-set modest cigarett declin
unfavor regul disrupt excis tax hike gain illicit trade risk profit
altria commerci tobacco product us brand like marlboro skoal
price close septemb
price target
ep current multipl
ep expect altria deliv
three-year averag sale growth
revenu exclud excis tax
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
iqo
launch atlanta
iqo test launch atlanta underway expect nation expans unlik e-
cigarett iqo tobacco base histor less appeal non-smok outsid
us issu youth use countri compel
reduced-risk product global revenu pm altria licens
right us iqo approv market us fda still
review applic modifi risk tobacco product vapor product fall favor
regul gener public could boost consum interest iqo especi
receiv approv market modifi risk claim
recent lung ill associ vape emerg recent suddenli even
though vapor product avail scale year like black market
product appear least primarili black market product nonetheless regul
consum call product question lump nicotin vapor product togeth
product caus confus consum continu believ public health
england point appropri produc nicotin vapor product less
harm smoker cigarett regul understand want take kind
action appear target nicotin vapor may remain pressur near-term
 crosthwait background altria could prove help senior vice presid
chief strategi growth offic led expans e-cigarett led regulatori effort
relat us iqo launch
page
excis tax rev
good
cog percent sale
net incom attrib noncontrol int
net incom attrib altria
earn attribut share-bas award
current disclosur inform compani found www piperjaffray com/researchdisclosur
